APEX1 and acute promyelocytic leukemia: Pharmacologically inhibiting the redox function of APE1/Ref-1 may be beneficial for the treatment of various cancers, as the inhibition of APE1/Ref-1 has been associated with enhanced colorectal cancer tumor regression in preclinical studies and enhanced promyelocytic leukemia response to treatment [15,38,64].